Recently initiated international registries and biobanks, such as the International Guillain-Barré Syndrome Outcome Study (IGOS) [71], Inflammatory Neuropathy Consortium Base (INCbase) [72], and IgM Anti-MAG peripheral Neuropathy: from proper assessment to trial Needs (IMAGiNe) study [73], will allow collection of standardized clinical data and biomaterial of large numbers of patients that will surely speed up biomarker discovery in the next decade. The gene discussed is CD40LG; the disease is peripheral neuropathy.